Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.37 |
| ▸ | LIPC | P11150 | 2/20 | 0.37 |
| ▸ | HSD17B13 | Q7Z5P4 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12862295 | 0.92 | PIK3CD (0.39) | SMN1; SMN2HSD17B13PIK3CDPIK3CBLMNA | |
| SCHEMBL1150831 | 0.92 | HSD17B13 (0.36) | SMN1; SMN2HSD17B13HSP90AA1PIK3CDPIK3CB | |
| SCHEMBL1151099 | 0.89 | CRHBP (0.40) | HSD17B13PIK3CDPIK3CBALDH1A1MAPT | |
| SCHEMBL1150957 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2LIPGHSD17B13PIK3CDPIK3CB | |
| SCHEMBL12874724 | 0.85 | HSP90AA1 (0.35) | SMN1; SMN2LIPGHSD17B13HSP90AA1PIK3CD | |
| SCHEMBL1150754 | 0.84 | ALDH1A1 (0.34) | SMN1; SMN2HSP90AA1LMNASCDALDH1A1 | |
| SCHEMBL12861859 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD17B13HSP90AA1PIK3CDPIK3CB | |
| SCHEMBL12861820 | 0.82 | GRIN2B (0.38) | SMN1; SMN2PIK3CDPIK3CBLMNA | |
| SCHEMBL823398 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B13HSP90AA1LMNASCD | |
| SCHEMBL1361748 | 0.82 | NR1I3 (0.42) | SMN1; SMN2LIPGLIPCHSD17B13HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| EP-2291377-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | Avexa Limited (AU) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | TPMT, DPYD, IMPDH1 | SMN1; SMN2 958/4885LIPG 4582/4885LIPC 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.